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Edited by Robert BaroukiAbstract Interleukin-1 receptor antagonist (IL-1ra) has been
shown to play a crucial role in the prevention of various inﬂam-
matory diseases. There is also convincing evidence that IL-1ra is
able to counteract inﬂammatory eﬀects of IL-1 members impli-
cated in insulin resistance and diabetes. However, the use of
knock-out animal models provides evidence to the contrary and
the role of IL-1ra in obesity-linked anomalies remains controver-
sial.
This minireview gets an insight into recent ﬁndings on the
implication of IL-1ra and its gene polymorphism in diabetes
and obesity, discusses the potential dual eﬀects of IL-1ra ob-
served in diﬀerent models, and comments on future directions.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Many pro-inﬂammatory cytokines such as tumor necrosis
factor alpha (TNF-a) and IL-6 are secreted by adipocytes
and have attracted considerable attention as mediators or
coordinators of the insulin resistance observed in inﬂamma-
tory diseases and obesity (for reviews see [1,2]). IL-1, one of
the major proinﬂammatory cytokines, is increased in diabetic
patients as well as in patients with rheumatoid arthritis or can-
cer [3]. IL-1 has been shown to promote b-cell destruction in
the pathogenesis of type 1 diabetes [4]. Recent reports have
illuminated the mechanisms of IL-1-induced insulin resistance
[5] and the role of IL-1 in pancreatic b-cell destruction in non-
obese diabetic (NOD) mice [6]. Since inﬂammatory mediators
trigger islet b-cell apoptosis in both type 1 and 2 diabetes [7],
anti-inﬂammatory therapeutic approaches could be a signiﬁ-
cant new development.Abbreviations: IL-1ra, interleukin-1 receptor antagonist; TNF-a,
tumor necrosis factor alpha; IFNc, interferon gamma; PPARc, per-
oxisome proliferator-activated receptor gamma; NF-jB, nuclear factor
kappa B; NOD, non-obese diabetic; WAT, white adipose tissue
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The interleukin-1 receptor antagonist (IL-1ra) belongs to the
IL-1 family and binds to IL-1 receptors without inducing a cel-
lular response, thereby antagonizing competitively the inﬂam-
matory eﬀects of IL-1a and -b [8]. Thus, IL-1ra is a naturally
occuring inhibitor, which is unique in the cytokine world. An
excess of IL-1ra is necessary to counteract the eﬀects of IL-1
in vitro.
Cells known to secrete IL-1ra include immune cells [9–11],
epithelial cells [12,13] skin keratinocytes [14], stromal cells
[15–18], hepatocytes [19] and adipocytes [20].
Since it does not induce signal transduction, the ‘‘activity’’ of
IL-1ra is regulated only by its levels of production which are
controlled by regulatory molecules (inhibitors and enhancers).
A dysregulation in the balance between IL-1 and IL-1ra is one
of the factors inﬂuencing the course, the susceptibility to and
the severity of many diseases [21]. In the past few years, IL-
1ra has attracted considerable clinical attention because its
serum levels are elevated in pathologies as diverse as sepsis,
cancer, metabolic diseases and auto-immune diseases [22–25];
whereas the plasma IL-1ra/IL-1 ratio in a healthy population
is close to 1 and exhibits minimal variation [26]. The increase
in circulating IL-1ra levels corresponds to a delayed event in
response to IL-1 production and may represent a preventive
mechanism in long-acting and/or excessive inﬂammatory
response. IL-1ra is sometimes considered as an acute phase
protein because its expression is regulated by proinﬂammatory
cytokines in hepatocytes [19].
In contrast, the inﬂammatory site is more likely unbalanced
in favor of IL-1, especially in severe lesions [27–30] and insuf-
ﬁcient production of endogenous IL-1ra may contribute to the
pathogeny of these conditions.3. IL-1ra and diabetes
An imbalance between IL-1ra and IL-1 may predispose to
the development of type 1 diabetes since very high levels of
IL-1ra are required to block the IL-1-induced decrease in insu-
lin secretion by pancreatic b-cells in vitro [31] or to inhibit the
injurious eﬀects of IL-1 on b cell function [32]. Moreover, an
imbalance of IL-1ra/IL-1 in favour of the pro-inﬂammatory
cytokine is observed in both the serum and LPS-stimulated
peripheral blood cells from patients with early type 1 diabetes
while an increase in circulating concentrations of IL-1ra in
long-standing diabetes suggests a sustained role of IL-1rablished by Elsevier B.V. All rights reserved.
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protective role of IL-1ra in the development of type 1 diabetes.
In mice, treatment with IL-1ra prevented streptozotocin-
induced diabetes and inhibited recurrence of diabetes after
pancreatic islet transplantation in spontaneously diabetic
NOD mice [34,35]. More recently, IL-1ra gene delivery to
human islets in culture was reported to prevent cell apoptosis
[36] and to increase cell replication in rat pancreatic islets [37].
Taken together, these results suggest that an increase in IL-
1ra production could be a response to immuno-inﬂammatory
activation present at the onset of type 1 diabetes.
Recent work has demonstrated that leptin, another adipo-
cytokine involved in the pathogenesis of insulin resistance,
induces b-cell apoptosis and impairs b-cell function via IL-1b
signalling in human islets [38]. Leptin decreases b-cell produc-
tion of IL-1ra and induces IL-1b release. Accordingly, the
expression of IL-1ra by human pancreatic b-cells is down-reg-
ulated in type 2 diabetic patients [38]. Interestingly, two inde-
pendent studies show that patients with type 2 diabetes have
signiﬁcantly lower plasma levels of IL-1ra than non-diabetic
patients while IL-1b plasma levels are similar in patients and
in controls [39,40]. However, the source of systemic cytokines
in these studies remains to be determined.4. IL-1ra and obesity
In patients with hyperleptinemic obesity, serum levels of IL-
1ra are 7-fold higher as compared to non-obese patients (1750
vs 250 pg/ml) and decrease after weight loss from bypass sur-
gery [41]. In this study, IL-1ra concentrations correlated with
lean body mass index, the degree of insulin resistance and lep-
tin levels.
Inmorbid obesity, leptinmay exert its eﬀects through the IL-1
pathway and IL-1ra may contribute to central leptin resistance
in obesity [42] because (i) IL-1ra crosses the blood/brain barrier
[43]; (ii) leptin induces IL-1ra expression in the brain – including
hypothalamus [44], (iii) injection of IL-1ra into the cerebral ven-
tricles inhibits the leptin-induced reduction in food intake [45].
Recent ﬁndings showed that white adipose tissue (WAT) is a
major source of IL-1ra [46]. IL-1ra is mostly secreted by the adi-
pocyte fraction of WAT and to a minor extent by the stromal
fraction [20]. In human WAT explants, IL-1ra secretion is in-
duced by LPS, IL-1 and IFNb through a local paracrine/auto-
crine action since these regulatory molecules are produced by
stromal cells or by the adipocytes themselves [20]. In this study,
peroxisome proliferator-activated receptor gamma (PPARc)
ligands failed to induce the secretion of IL-1ra whereas they
strongly enhance IL-1ra secretion in human monocytes [47].
The adipo-insular axis plays an important role during the
development of type 2 diabetes in obese patients. IL-1ra being
modulated by leptin in b-cells may participate in the axis loop
by regulating adipocytokines production. The cross-talk
between IL-1ra and other adipocyte markers has not been
reported. In particular, IL-1ra expression after leptin exposure
was not investigated in human adipocytes.5. IL-1ra regulation and metabolic factors
Few studies address the cross-talk between IL-1ra and other
metabolic factors. To date, IL-1ra modulation by adiponectinhas been found in human leukocytes [48] whereas IL-1ra mod-
ulation by leptin is cell-speciﬁc since leptin decreases the
expression and secretion of IL-1ra in pancreatic islets but
increases it in monocytes [49] and macrophages [50].
In HepG2 and THP-1 cells, the activation of the IL-1ra pro-
moter by leptin involves the activation of MAPK and the bind-
ing of a yet uncharacterized factor to the nuclear factor kappa
B (NF-jB) binding site of the IL-1ra promoter [51].
In hepatocytes, IL-1 and IL-6 stimulate IL-1ra gene tran-
scription and this stimulation is mediated by activation of
NF-jB and CEBP. Interactions between these two transcrip-
tion factors have been suggested to mediate the synergistic ef-
fects of IL-1 and IL-6 on acute phase protein production [19].
Long-term IL-1a stimulation of 3T3-L1 adipocytes induces
SOCS-1 and -3 while acute IL-1a treatment was recently re-
ported to cause insulin resistance at diﬀerent levels [5]: (i) by
reducing tyrosine phosphorylation of IRS-1 and its association
with PI3-kinase; (ii) by stimulating Ser-307 phosphorylation of
IRS-1 via the activation of several serine kinases (IKK, JNK,
ERK and p70S6K); (iii) by inhibiting PKB/Akt phosphoryla-
tion in synergy with IL-6.
Thus, examining signalling pathway modulation by IL-1ra
is also of particular interest in order to elucidate how IL-1ra
counteracts IL-1-induced insulin resistance.6. IL-1ra knock out mice
Recently, the IL-1ra / mouse has proven to be a good
model for investigating obesity, diabetes and lipid metabolism
disorders [52,53]. As previously described [54], mice lacking
IL-1ra have a lean phenotype due to a reduction in body fat
mass compared with wild-type controls. Surprisingly, these
mice also have an increased food intake relative to their body
weight when fed with a standard diet [53]. This could be a con-
sequence of an increased energy expenditure and of a signiﬁ-
cant reduction in blood leptin concentrations (6-fold lower
when compared with wild-type mice). Despite having also
decreased blood insulin levels, IL-1ra / mice have normal
serum glucose levels because of an increased insulin sensitivity.
Whether adipocyte diﬀerentiation is altered or not in IL-1ra
/ mice is controversial. Using histological analysis of adi-
pose tissue, Matsuki et al. previously reported that adipocytes
of IL-1ra / mice under fed conditions exhibited normal
morphology and cell volume as those of wild-type mice.
According to more recent work [53], IL-1ra / mice have
reduced adipose storage, impaired adipogenesis (associated
with reduced gene expression of adipocyte diﬀerentiation
markers LPL, Krox20, C/EBPa and PPARc) and a 77%
decrease in adipocyte size.
Heterozygous IL-1ra +/mice also have impaired adipogen-
esis but have unaltered fat mass [53]. The authors suggest that
in these mice, the adipocyte hypotrophy may be compensated
by an increase in adipocyte recruitment due to a relative bal-
ance between IL-1 and IL-1ra (ratio close to 1). On the other
hand, the circulating IL-1 excess in IL-1ra / mice prevents
adipogenesis and this IL-1 oversignalling may also lead to
reduced fat mass and WAT stores.
IL-1ra gene deletion in IL-1ra / mice did not result in a
general inﬂammatory state since circulating levels of pro-
inﬂammatory cytokines including IL-1 are not signiﬁcantly dif-
ferent from those in wild-type mice. However, the resulting
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may explain the inhibition in LPL expression and activity, lead-
ing to the suppression of fat accumulation, and may cause the
suppression of weight gain, whereas a 2.6-fold molar excess of
serum IL-1ra concentration in the wild-type mice may be suﬃ-
cient to block IL-1 activity at a systemic and/or local levels [53].
The decrease in insulin secretion may cause the defect in lipid
accumulation found in adipose tissue of these mice. Taken
together, these results suggest that endogenous IL-1ra is a
pro-adipogenic factor and markedly increased circulating IL-
1ra levels in obese humans might contribute to obesity-associ-
ated anomalies, including an acquired resistance to leptin.7. IL-1ra gene polymorphism and metabolic diseases
The human IL-1ra gene (IL1RN) has a variable length poly-
morphism within intron 2 due to variation in the number of
copies of an 86 bp sequence. To date, six distinct alleles corre-
sponding to 1, 2, 3, 4, 5 and 6 copies of the repeat sequence
have been identiﬁed [55]. The 4-repeat (IL1RN*1) and 2-repeat
(IL1RN*2) alleles are those most frequently found in the gen-
eral population while the other four alleles are rarely observed.
The number of repeats at the polymorphism site may be of
functional signiﬁcance because the repeated sequence contains
possible binding sites for transcription factors [56]. Indeed, IL-
1ra allele 2 has a clear inﬂuence on IL-1ra circulating levels
since in normal human subjects, its carrier individuals had
10-fold higher levels than the non-carrier individuals (745 ng/
ml vs 627 pg/ml) [57]. Moreover, a signiﬁcant increase in fre-
quency and/or carriage rate of IL1RN*2 has been reported
to be associated with more severe clinical outcome in various
disorders (references in database http://www.nanea.dk/cyto-
kinesnps/) including non-insulin dependent diabetes mellitusFig. 1. Proposed model outlining the dual action played by IL-1ra in hum
(mainly IL-1 and leptin) in various cell types from diﬀerent organ system
protective eﬀects. Details of the features described in this ﬁgure are given an[58]. IL1RN*2 is the ﬁrst such marker outside the MHC related
to disease severity.
Although there is no evidence for overall linkage or intra-
familial association between IL-1ra polymorphism and type
1 diabetes [59], an increased frequency of the IL1RN*1/
IL1RN*1 genotype was observed [60]. In this study, patients
with type 1 diabetes carrying this genotype had also 30% lower
levels of plasma IL-1ra compared with levels in patients carry-
ing the IL1RN*1/IL1RN*2 genotype. This ﬁnding suggests an
enhancing eﬀect of IL1RN*2 allele on IL-1ra circulating levels
in type 1 diabetes patients as observed in healthy carriers.
However, this enhancing eﬀect may be inﬂuenced by other fac-
tors including IL-1 beta genes [57].
The association between IL-1ra polymorphism and type 2
diabetes has not been reported whereas the relative risk of
obesity in comparison with lean group tends to be higher in
IL1RN*2 carriers but without reaching signiﬁcance [61].8. Conclusions and future directions
In recent years, an important experimental approach has
been undertaken by many groups to study the role of IL-1ra
in metabolic diseases (summarized in Fig. 1). It is now clear
that IL-1ra has a protective role in pancreatic cells and recom-
binant IL-1ra, which is currently used as a therapeutic mole-
cule in rheumatoid arthritis [62] may be a potential drug in
the treatment of diabetes by controlling its local delivery in
IL-1ra deﬁcient pancreatic cells from microencapsulated genet-
ically engineered cells [63].
In contrast, results using the generation of mouse models
with altered IL-1ra result in strong adipocyte hypotrophy
and decrease in blood leptin levels, suggesting that endogenous
IL-1ra is a pro-adipogenic factor contributing to central leptinan metabolic diseases. IL-1ra is modulated by other adipocytokines
s, and coordinates ubiquitous reactions leading to either harmful or
d referenced in the text.
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duces adipocyte diﬀerentiation needs to be conﬁrmed but is
likely since IL-1b, TNF-a and IL-6 inhibit 3T3 pre-adipocytes
diﬀerentiation along with decreased insulin-stimulated glucose
uptake, GLUT-4 and C/EBPa expression [64–66]. The inhibi-
tion of adipogenesis by IL-1 and TNF-a in these cells is med-
iated by suppressing PPARc function through NF-jB
activated by the TAK-1/TAB1/NIK cascade [67] and reversed
by troglitazone [65]. The eﬀect of IL-1ra on this signalling
pathway (possibly in synergy with troglitazone) as well as on
the expression of other adipocyte speciﬁc genes (LPL, Wnt,
Pref-1, SREBP, adiponectin) should gain further important
insights into the fundamental physiological process of adipo-
genesis regulation by the IL-1/IL1ra balance.
The discrepancy regarding circulating IL-1ra that is de-
creased in type 2 diabetes and increased in obesity is intriguing
and may reﬂect diﬀerent mechanisms in distinct pathologies.
Obesity is characterised by an excess in blood leptin, which
is now considered as a pro-inﬂammatory adipocytokine [68].
Increased circulating IL-1ra levels in obese patients may have
a protective role in response to high leptin levels and pertain to
its immunomodulatory and/or metabolic activities as described
in sepsis or inﬂammatory disorders [2].
Recent data indicate that obese WAT is inﬁltrated by
macrophages, which are a major source of locally-produced
pro-inﬂammatory cytokines, including IL-1 (review in [69]).
Interestingly, weight loss is associated with a reduction in
the macrophage inﬁltration of WAT and an improvement of
the inﬂammatory proﬁle of gene expression. As IL-1ra concen-
trations are also reduced after weight loss, they probably re-
spond to the IL-1 signal during the course of the disease and
the circulating IL-1ra in obesity may come from the inﬂamma-
tory cells rather than from adipocytes. In contrast, the human
pancreatic b-cells are the main source of IL-1ra in type 2 dia-
betes, where IL-1ra expression is down-regulated. These results
predict a distinct regulation of IL-1ra between the diﬀerent cell
types (inﬂammatory cells, b-cells and adipocytes) and it would
be important to further characterize IL-1ra in these cells.
We have previously found a dichotomy between the systemic
production of IL-1ra and its local production at the inﬂamma-
tory site, and suggested separate regulatory mechanisms in dif-
ferent compartments [25]. In this study, the IL1RN*2 allele
was shown to accentuate this dichotomy. Similarly, circulating
levels of IL-1ra are elevated in type 1 diabetic patients (espe-
cially those with IL-1RN*2) while a deﬁciency in IL-1ra secre-
tion takes place in the pancreatic cells and may be inﬂuenced
by IL1RN*2.
Lately, the understanding of the molecular mechanisms by
which the IL-1 family members modulate food intake and en-
ergy expenditure has progressed rapidly. However, many ques-
tions still remain only partly answered as contradictory results
appear on the role of IL-1ra in these mechanisms: First, a role
for IL-1ra in the regulation of body weight has been suggested
and the balance of IL-1/IL-1ra appears crucial in this function
but still, a lack of IL-1 signalling does not aﬀect the mainte-
nance of body weight as reported in IL-1 / mice [70] or in
transgenic mice overexpressing IL-1ra [54]; Second, chronic
central administration of recombinant IL-1ra does not aﬀect
food intake in rats [71] while IL-1ra deﬁcient animal models
suggest an eﬀect on food intake; Third, IL-1ra prevents IL-1
mediated b-cell apoptosis in pancreatic islets but IL-1ra deﬁ-cient mice show no pancreatic alteration in term of islets mor-
phology as well as insulin storage in b-cells [72].
Further studies will be necessary to clarify these points and
would allow a better general understanding on the complex
regulation of IL-1ra and its implication in insulin resistance
and obesity-linked diseases.
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